Related Experiment Video

Updated: Aug 18, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Unscheduled expression of cyclins by anti-cancer drug exposure

A Yoshizaki1, T Honda, Y Utsugisawa

  • 1Department of Obstetrics and Gynecology Iwate Medical University.

Human Cell
|August 26, 1998
PubMed

Insights

Taxol (TXL) alters cyclin D1 and B1 expression in human ovarian cancer cells. TXL exposure increased cyclin expression in KFr13 cells and decreased cyclin B1 in OVCAR-3 cells, impacting cell cycle progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Cyclin expression is crucial for cell cycle regulation in normal and cancerous cells.
  • Unscheduled cyclin expression is a hallmark of certain cancers and can be induced by anti-cancer drugs.
  • Understanding cyclin dynamics under drug treatment is vital for cancer therapy.

Purpose of the Study:

  • To investigate the effects of cytotoxic concentrations of Taxol (TXL) on cyclin D1 and B1 expression in human ovarian cancer cell lines.
  • To compare the differential responses of distinct ovarian cancer cell lines to TXL-induced cyclin modulation.

Main Methods:

  • Treatment of human ovarian cancer cell lines (KFr13 and OVCAR-3) with cytotoxic concentrations of Taxol (1 microM).
  • Analysis of cyclin D1 and cyclin B1 expression levels across different cell cycle phases (G0+1, S, G2+M) using flow cytometry or Western blotting.
  • Comparison of protein expression in TXL-treated cells versus control groups.

Main Results:

  • In KFr13 cells, TXL exposure led to remarkable cyclin D1 and B1 expression in the G2+M phase.
  • OVCAR-3 cells exhibited high cyclin D1 and moderate cyclin B1 expression in controls.
  • TXL treatment in OVCAR-3 cells showed no significant change in cyclin D1 but decreased cyclin B1 in G0+1 and S phases, with moderate expression in G2+M.

Conclusions:

  • Taxol differentially affects cyclin D1 and B1 expression in human ovarian cancer cell lines.
  • The observed changes in cyclin expression by TXL suggest distinct mechanisms of action or cellular responses in different ovarian cancer subtypes.
  • These findings contribute to understanding the molecular basis of Taxol's efficacy and potential resistance mechanisms in ovarian cancer.

More Related Videos

Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols12:02

Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols

Published on: June 6, 2017

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids06:25

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids

Published on: June 14, 2021

Related Concept Videos

Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...